Acorda Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACORQ research report →
About the company
Acorda Therapeutics, Inc. operates as a biopharmaceutical enterprise focused on researching, developing, and bringing to market medical treatments for neurological conditions, predominantly in the United States. The company offers Ampyra (dalfampridine), an oral medication aimed at enhancing walking capabilities in adult patients experiencing multiple sclerosis.
- CEO
- Ron Cohen
- IPO
- 2006
- Employees
- 102
- HQ
- Pearl River, NY, US
Price Chart
- Market Cap
- $12.42K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.01
- EV/EBITDA
- -0.80
- Div Yield
- 0.00%
- Gross Margin
- 60.86%
- Op Margin
- -19.78%
- Net Margin
- -214.95%
- ROE
- 786.07%
- ROIC
- -25.57%
- Revenue
- $117.63M · -0.79%
- Net Income
- $-252,854,000 · -283.60%
- EPS
- $-203.59 · -204.32%
- Op Income
- $-23,264,000
- FCF YoY
- 32.35%
- 52W High
- $18.00
- 52W Low
- $0.01
- 50D MA
- $0.15
- 200D MA
- $7.10
- Beta
- 1.69
- Avg Volume
- 22.12K
Get TickerSpark's AI analysis on ACORQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ACORQ coverage
Recent articles, reports, and earnings notes.
No research on ACORQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACORQ report →Similar companies
Peers in the same neighborhood.